Literature DB >> 3183381

Human C5a and C5a des Arg exhibit chemotactic activity for fibroblasts.

R M Senior1, G L Griffin, H D Perez, R O Webster.   

Abstract

C5a and C5a des Arg are chemotactic factors for inflammatory cells but it is not known whether these agents are chemoattractants for fibroblasts. Accordingly, C5a, purified from zymosan-activated human, and C5a des Arg, prepared by incubating C5a with immobilized porcine carboxypeptidase B, were studied for fibroblast chemotactic activity. We observed that both C5a and C5a des Arg stimulated human skin fibroblasts and fetal bovine ligament fibroblasts to migrate in a concentration-dependent fashion, and that the migratory responses were similar in magnitude to the responses achieved with optimal concentrations of two known fibroblast chemoattractants, platelet-derived growth factor and human fibrinopeptide B. The peak responses to C5a and C5a des Arg occurred at approximately 10(-9)M. With ligament fibroblasts, there was a greater response to C5a des Arg than to C5a, but with human fibroblasts there was no difference. Cochemotaxin, which enhances the chemotactic activity of C5a des Arg for neutrophils, had no effect on C5a des Arg fibroblast chemotactic activity but appeared to increase the fibroblast chemotactic activity of C5a. These results indicate that the effects of C5a and C5a des Arg in vivo may extend to the recruitment of mesenchymal cells. Moreover, the findings represent another example of an activity retained by C5a after removal of its carboxyl terminal arginine.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3183381

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Selective inhibition of the C5a chemotactic cofactor function of the vitamin D binding protein by 1,25(OH)2 vitamin D3.

Authors:  Anisha B Shah; Stephen J DiMartino; Glenda Trujillo; Richard R Kew
Journal:  Mol Immunol       Date:  2005-08-22       Impact factor: 4.407

2.  Upregulation of vitamin D binding protein (Gc-globulin) binding sites during neutrophil activation from a latent reservoir in azurophil granules.

Authors:  Stephen J DiMartino; Glenda Trujillo; Lauren A McVoy; Jianhua Zhang; Richard R Kew
Journal:  Mol Immunol       Date:  2006-11-20       Impact factor: 4.407

3.  Cofactor regulation of C5a chemotactic activity in physiological fluids. Requirement for the vitamin D binding protein, thrombospondin-1 and its receptors.

Authors:  Glenda Trujillo; Jianhua Zhang; David M Habiel; Lingyin Ge; Mahalakshmi Ramadass; Berhane Ghebrehiwet; Richard R Kew
Journal:  Mol Immunol       Date:  2011-10-19       Impact factor: 4.407

4.  Fibroblast chemotaxis induction by human recombinant interleukin-4. Identification by synthetic peptide analysis of two chemotactic domains residing in amino acid sequences 70-88 and 89-122.

Authors:  A E Postlethwaite; J M Seyer
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

Review 5.  Complement Receptors in Myeloid Cell Adhesion and Phagocytosis.

Authors:  Michael L Dustin
Journal:  Microbiol Spectr       Date:  2016-11

6.  Neutrophil recruitment to the lung in both C5a- and CXCL1-induced alveolitis is impaired in vitamin D-binding protein-deficient mice.

Authors:  Glenda Trujillo; David M Habiel; Lingyin Ge; Mahalakshmi Ramadass; Nancy E Cooke; Richard R Kew
Journal:  J Immunol       Date:  2013-06-10       Impact factor: 5.422

7.  A Comparative Study of Impedance versus Optical Label-Free Systems Relative to Labelled Assays in a Predominantly Gi Coupled GPCR (C5aR) Signalling.

Authors:  Reena Halai; Daniel E Croker; Jacky Y Suen; David P Fairlie; Matthew A Cooper
Journal:  Biosensors (Basel)       Date:  2012-07-26

8.  Enzyme kinetic and binding studies identify determinants of specificity for the immunomodulatory enzyme ScpA, a C5a inactivating bacterial protease.

Authors:  Malgorzata Teçza; Todd F Kagawa; Monica Jain; Jakki C Cooney
Journal:  Comput Struct Biotechnol J       Date:  2021-04-17       Impact factor: 7.271

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.